Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Benzathine Benzylpenicillin→

Benzathine Benzylpenicillin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1538-09-6
Molecular formula
C48H56N6O8S2
Molecular weight
909.1 g/mol
Drug class
Natural penicillin (penicillin G)beta-lactam antibacterial
Mechanism of action
Binds penicillin-binding proteins and inhibits transpeptidation during bacterial peptidoglycan synthesis, weakening the cell wall and producing bactericidal activity in susceptible organisms.
Indications / reported uses
  • Treatment of infections caused by benzylpenicillin-susceptible bacteria, including selected streptococcal, pneumococcal, meningococcal, clostridial and spirochaetal infections; the exact indication, route and regimen depend on the clinical setting and formulation

Sources: UK SmPC — Benzylpenicillin sodium · NHS — Benzylpenicillin · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Benzathine Benzylpenicillin Environmental Risk Assessment (ERA) (the Benzathine Benzylpenicillin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.